Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 4/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9901268 | 1.00 | TYK2 (0.42) | TYK2PIM1PIM2PIM3HTR6 | |
| SCHEMBL9904399 | 0.83 | TYK2 (0.62) | TYK2PIM1PIM2PIM3CHEK2 | |
| SCHEMBL9904397 | 0.83 | TYK2 (0.62) | TYK2PIM1PIM2PIM3CHEK2 | |
| SCHEMBL9942550 | 0.82 | CHEK2 (0.37) | TYK2PIM1PIM2PIM3HTR6 | |
| SCHEMBL9904525 | 0.81 | PIK3CD (0.39) | PIM1PIM2HTR6BCHEPIK3CD | |
| SCHEMBL9904528 | 0.81 | PIK3CD (0.39) | PIM1PIM2HTR6BCHEPIK3CD | |
| SCHEMBL9904423 | 0.79 | TYK2 (0.58) | TYK2PIM1PIM2PIM3CHEK2 | |
| SCHEMBL9905828 | 0.79 | TYK2 (0.58) | TYK2PIM1PIM2PIM3CHEK2 | |
| SCHEMBL9904579 | 0.78 | CTPS1 (0.38) | PIM1PIM2HTR6BCHEPIK3CD | |
| SCHEMBL9904582 | 0.78 | CTPS1 (0.38) | PIM1PIM2HTR6BCHEPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2796456-A1 | Bicyclic compounds as Pim inhibitors | Amgen Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| EP-2796456-A1 | Bicyclic compounds as Pim inhibitors | Amgen Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2649065-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | PIM1, PIM2, PIM3 | TYK2 290/4885PIM1 1/4885PIM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.